Patents by Inventor Gregory Hinkle

Gregory Hinkle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Angiotensinogen (AGT) iRNA compositions and methods of use thereof
    Patent number: 11015201
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the AGT gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an AGT gene and to methods of preventing and treating an AGT-associated disorder, e.g., high blood pressure.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: May 25, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Donald Foster, Gregory Hinkle, Mark K. Schlegel
  • POLYNUCLEOTIDE AGENTS TARGETING SERPINC1 (AT3) AND METHODS OF USE THEREOF
    Publication number: 20210123049
    Abstract: The invention relates to polynucleotide agents targeting the Serpinc1 (AT3) gene, and methods of using such polynucleotide agents to inhibit expression of Serpinc1 and to treat subjects having a bleeding disorder, e.g., a hemophilia.
    Type: Application
    Filed: July 10, 2020
    Publication date: April 29, 2021
    Inventor: Gregory Hinkle
  • Polynucleotide agents targeting programmed cell death 1 ligand 1 (PD-L1) and methods of use thereof
    Patent number: 10982215
    Abstract: The invention relates to polynucleotide agents targeting programmed cell death 1 ligand 1 (PD-L1) gene, and methods of using such polynucleotide agents to inhibit expression of PD-L1 and to treat subjects having a PD-L1-associated disorder.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: April 20, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventor: Gregory Hinkle
  • APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20210108203
    Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the apolipoprotein C3 (APOC3) gene, and methods of using such RNAi agents to inhibit expression of APOC3 and methods of treating subjects having an APOC3 associated disorder, e.g., hypertriglyceridemia.
    Type: Application
    Filed: December 21, 2020
    Publication date: April 15, 2021
    Inventors: Kevin Fitzgerald, William Querbes, James Butler, Stephanie Williams, Abigail Liebow, Gregory Hinkle, Martin A. Maier, Stuart Milstein, Satyanarayana Kuchimanchi, Muthiah Manoharan
  • Polynucleotide agents targeting aminolevulinic acid synthase-1 (ALAS1) and uses thereof
    Patent number: 10968452
    Abstract: The invention relates to polynucleotide agents, e.g., antisense polunucleotide agents, targeting the ALAS1 gene, and methods of using such agents to alter (e.g., inhibit) expression of ALAS1 and to treat ALAS1 associated diseases, e.g., porphyria.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: April 6, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventor: Gregory Hinkle
  • ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20210095290
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the AGT gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an AGT gene and to methods of preventing and treating an AGT-associated disorder, e.g., high blood pressure.
    Type: Application
    Filed: November 10, 2020
    Publication date: April 1, 2021
    Inventors: Donald Foster, Gregory Hinkle, Mark K. Schlegel
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE
    Publication number: 20210095289
    Abstract: The invention relates to antisense polynucleotide agents targeting the LECT2 gene, and methods of using such anti sense polynucleotide agents to inhibit expression of LECT2 and to treat subjects having a LECT2-associated disease, e.g., amyloidosis.
    Type: Application
    Filed: July 13, 2020
    Publication date: April 1, 2021
    Inventor: Gregory Hinkle
  • COMPOSITIONS AND METHODS DIRECTED TO TREATING LIVER FIBROSIS
    Publication number: 20210087218
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the COL1A1, TGF-?, and SMAD2/3 genes, and methods of using such dsRNA compositions to inhibit expression of COL1A1, TGF-?, and SMAD2/3.
    Type: Application
    Filed: May 6, 2020
    Publication date: March 25, 2021
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Gregory Hinkle, Victor Kotelianski, Brian Bettencourt, Alfica Sehgal, Tatiana Novobrantseva
  • GNAQ targeted dsRNA compositions and methods for inhibiting expression
    Patent number: 10954516
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: March 23, 2021
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Jared Gollob, Gregory Hinkle, Ivanka Toudjarska, David Bumcrot
  • Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, HAO1) and methods of use thereof
    Patent number: 10946107
    Abstract: The invention relates to polynucleotide agents targeting an hydroxyacid oxidase (HAO1) gene, and methods of using such polynucleotide agents to inhibit expression of HAO1 and to treat subjects having an HAO1-associated disease, e.g., hyperoxaluria.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: March 16, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventor: Gregory Hinkle
  • Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof
    Patent number: 10934544
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1) gene, the Factor XII (Hageman Factor (F12) gene, or the Kininogen 1 (KNG1) gene, and methods of using such RNAi agents to inhibit expression of a KLKB1 gene, an F12 gene, and/or a KNG1 gene, and methods of treating subjects having an hereditary angioedema (HAE) and/or a contact activation pathway-associated disorder.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: March 2, 2021
    Assignee: Alny lam Pharmaceuticals, Inc.
    Inventors: Akin Akinc, Gregory Hinkle, Martin A. Maier, James Butler, Jingxuan Liu
  • ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20210046187
    Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the angiotensinogen (AGT) gene, and methods of using such RNAi agents to inhibit expression of AGT and methods of treating subjects having an AGT-associated disorder, e.g., hypertension.
    Type: Application
    Filed: September 15, 2020
    Publication date: February 18, 2021
    Inventors: Donald Foster, Brian Bettencourt, Klaus Charisse, Gregory Hinkle, Satyanarayana Kuchimanchi, Martin A. Maier, Stuart Milstein
  • Serpina1 iRNA compositions and methods of use thereof
    Patent number: 10920223
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: February 16, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Alfica Sehgal, Klaus Charisse, Brian Bettencourt, Martin A. Maier, Kallanthottathil G. Rajeev, Gregory Hinkle, Muthiah Manoharan
  • Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof
    Patent number: 10889813
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the programmed cell death 1 ligand 1 (PD-L1) gene, and methods of using such RNAi agents to inhibit expression of a PD-L1 gene and methods of treating subjects having a PD-L1-associated disorder.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: January 12, 2021
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventor: Gregory Hinkle
  • STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20210002638
    Abstract: The invention relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting the SCAP gene, as well as methods of inhibiting expression of a SCAP gene and methods of treating subjects having a SCAP-associated disorder, such as nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), using such dsRNAi agents and compositions.
    Type: Application
    Filed: July 27, 2020
    Publication date: January 7, 2021
    Inventors: Kevin Fitzgerald, Huilei Xu, Gregory Hinkle
  • Polynucleotide agents targeting factor XII (hageman factor) (F12) and methods of use thereof
    Patent number: 10883107
    Abstract: The invention relates to polynucleotide agents targeting Factor XII (F12) gene, and methods of using such polynucleotide agents to inhibit expression of Factor XII and to treat subjects having a Factor XII-associated disease, e.g., heredity angioedema (HAE), prekallikrein deficiency, malignant essential hypertension, hypertension, end stage renal disease, or Fletcher Factor Deficiency.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: January 5, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventor: Gregory Hinkle
  • KISSPEPTIN 1 (KISS1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20200385719
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the KISS1 gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a KISS1 gene and to methods of preventing and treating a deficiency in glycemic control, e.g., type 2 diabetes mellitus (T2DM).
    Type: Application
    Filed: November 15, 2018
    Publication date: December 10, 2020
    Inventors: Mangala Meenakshi Soundarapandian, Gregory Hinkle
  • POLYNUCLEOTIDE AGENTS TARGETING ANGIOTENSINOGEN (AGT) AND METHODS OF USE THEREOF
    Publication number: 20200384011
    Abstract: The invention relates to polynucleotide agents, e.g., antisense polynucleotide agents, targeting an angiotensinogen (AGT) gene, and methods of using such polynucleotide agents to inhibit expression of AGT and to treat subjects having an AGT-associated disease, e.g., hypertension.
    Type: Application
    Filed: August 20, 2020
    Publication date: December 10, 2020
    Inventor: Gregory Hinkle
  • Glucokinase (GCK) iRNA compositions and methods of use thereof
    Patent number: 10844384
    Abstract: The invention relates to double stranded ribonucleic acid (dsRNA) compositions targeting a glucokinase (GCK) gene, as well as methods of inhibiting expression of a glucokinase (GCK) gene, and methods of treating subjects having a glycogen storage disease (GSD), e.g., type Ia GSD.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: November 24, 2020
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Kevin Fitzgerald, David Erbe, Gregory Hinkle
  • SERUM AMYLOID P COMPONENT (APCS) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20200345758
    Abstract: The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the serum amyloid P component (APCS) gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of an APCS gene and to treat subjects having an APCS-associated disease, e.g., amyloidosis, Alzheimer's disease or coronary atherosclerotic heart disease.
    Type: Application
    Filed: May 19, 2020
    Publication date: November 5, 2020
    Inventors: Kevin Fitzgerald, Gregory Hinkle